Briefing Calendar IPOs Opportunities Companies Compare Analytics Watchlist

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Loading market movers...

Free biotech catalyst calendar with AI-powered predictions. Track FDA decisions, PDUFA dates, clinical trial results, and Phase 3 readouts. Real-time alerts for biotech investors.

Quick Links

This Week's Catalysts
Full Calendar
Catalyst Types
Search Companies
Biotech Glossary
Embed Widget

Legal

About
ML Track Record
Privacy
Terms

Data Sources

ClinicalTrials.gov
SEC EDGAR
FDA

⚠️ Not Financial Advice (NFA)

CatalystAlert provides data aggregation and analysis tools only. All probability scores and predictions are based on historical data and are NOT guarantees of future results. Past performance does not indicate future success. We are not responsible for the accuracy of third-party data sources. Always consult a qualified financial advisor before making investment decisions.

© 2026 CatalystAlert. All rights reserved.

Data may be delayed or incomplete. Use at your own risk.

Fenebrutinib - Phase 3 | ROCHE Pipeline | CatalystAlert

Fenebrutinib

Phase 3

Roche Holding AG (ROCHE)

00%

Phase 3

Development Phase

1

Upcoming Catalysts

0

Historical Events

0

Regulatory Approvals

Upcoming Catalysts

6d

ROCHE⭐Phase 3

Fenebrutinib Phase 3 Results Expected

Fenebrutinib• Relapsing Multiple Sclerosis746

Jan 27

00%

Drug Information

Target Indication

Relapsing Multiple Sclerosis

Clinical Trial

Last updated: 1/2/2026

Developer

ROCHE

Roche Holding AG

Biotechnology•North America•NYSE

Related Pipeline

IbandronatePhase 3

Pain; Bone Neoplasms; Neoplasm Metastasis

RO7239361Phase 3

Duchenne Muscular Dystrophy

obinutuzumabPhase 3

Lymphocytic Leukemia, Chronic

Anemia

Peginterferon alfa-2aPhase 3

Hepatitis C, Chronic

View full pipeline